News | May 18, 2026
Alembic Pharma Q4 revenue rises to Rs. 1,848 crore
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Subscribe To Our Newsletter & Stay Updated
